ArticleFrontiers in oncology2025
The prognostic value of growth pattern-based grading for mucinous ovarian carcinoma (MOC): a systematic review and meta-analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the prognostic significance of expansile and infiltrative growth patterns in mucinous ovarian carcinoma (MOC). Methods: A systematic search was conducted in the PubMed, Embase, and Web of Science databases for studies published between January 1, 2010, and September 6, 2024, examining the correlation between expansile and infiltrative tumor growth patterns and prognosis in MOC. Subgroup analyses were performed for mortality, recurrence, and FIGO stage I based on tumor subtype. The Chi-square test was used to evaluate the distribution of expansile and infiltrative tumors across FIGO stages I-IV. Results: Twelve eligible studies, comprising a total of 1185 patients, were included in this systematic review and meta-analysis. The combined death rate in the expansile and infiltrative MOC was 10.5% (95%CI: 6.2-15.7) and 31.1% (95%CI: 14.1-50.9). The combined recurrence rate in the expansile and infiltrative MOC was 6.9% (95%CI: 3.1-11.9) and 24.5% (95%CI: 14.3-36.2). The combined International Federation of Gynecology and Obstetrics (FIGO) I rate in the expansile and infiltrative MOC was 89.8% (95%CI: 84.9-94.0) and 56.2% (95%CI: 41.5-70.4). A significant association was found between tumor type and FIGO stage (χ² (3) = 110.92, p < 0.00001). Conclusion: Expansile MOC predicts better outcomes, while infiltrative MOC is linked to advanced stages and poorer prognosis. Complete surgical staging is crucial for infiltrative MOC but optional for early-stage expansile MOC. Early-stage patients should consider fertility-sparing surgery, timely conception, and close recurrence monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.